PRA Health Sciences, Inc. (PRAH) Shares Sold by Century Capital Management LLC

Century Capital Management LLC reduced its position in PRA Health Sciences, Inc. (NASDAQ:PRAH) by 35.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,978 shares of the medical research company’s stock after selling 21,847 shares during the quarter. Century Capital Management LLC owned about 0.06% of PRA Health Sciences worth $2,924,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of PRA Health Sciences by 12.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after purchasing an additional 160 shares during the last quarter. Meeder Asset Management Inc. raised its stake in shares of PRA Health Sciences by 144.0% during the second quarter. Meeder Asset Management Inc. now owns 1,535 shares of the medical research company’s stock worth $115,000 after purchasing an additional 906 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in shares of PRA Health Sciences by 232.3% during the first quarter. Envestnet Asset Management Inc. now owns 1,844 shares of the medical research company’s stock worth $121,000 after purchasing an additional 1,289 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new stake in shares of PRA Health Sciences during the first quarter worth approximately $136,000. Finally, Teacher Retirement System of Texas purchased a new stake in shares of PRA Health Sciences during the first quarter worth approximately $208,000. 98.38% of the stock is owned by institutional investors and hedge funds.

In other PRA Health Sciences news, major shareholder Pra Investors L.P. Kkr sold 9,500,000 shares of the business’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $74.85, for a total transaction of $711,075,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Linda Baddour sold 100,000 shares of the business’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $74.85, for a total value of $7,485,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 10,000,000 shares of company stock valued at $748,500,000 in the last 90 days. Insiders own 2.10% of the company’s stock.

Several equities research analysts have recently commented on the company. SunTrust Banks, Inc. restated a “buy” rating on shares of PRA Health Sciences in a research note on Wednesday, August 9th. Zacks Investment Research cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Thursday. Bank of America Corporation assumed coverage on PRA Health Sciences in a research note on Monday, June 26th. They set a “buy” rating and a $89.00 price target for the company. Raymond James Financial, Inc. assumed coverage on PRA Health Sciences in a research note on Wednesday, August 16th. They set an “outperform” rating and a $89.00 price target for the company. Finally, BidaskClub cut PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $85.00.

PRA Health Sciences, Inc. (NASDAQ:PRAH) traded down 0.49% on Friday, reaching $77.02. The company’s stock had a trading volume of 368,930 shares. The firm has a market capitalization of $4.83 billion, a P/E ratio of 49.72 and a beta of 0.45. PRA Health Sciences, Inc. has a 52-week low of $49.29 and a 52-week high of $80.99. The firm has a 50-day moving average price of $75.79 and a 200 day moving average price of $69.67.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings data on Monday, August 7th. The medical research company reported $0.62 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.72 by $0.10. PRA Health Sciences had a net margin of 5.15% and a return on equity of 21.17%. The company had revenue of $457.90 million for the quarter, compared to analyst estimates of $447.79 million. During the same quarter in the prior year, the firm earned $0.63 EPS. The company’s revenue for the quarter was up .5% compared to the same quarter last year. Equities analysts anticipate that PRA Health Sciences, Inc. will post $3.19 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “PRA Health Sciences, Inc. (PRAH) Shares Sold by Century Capital Management LLC” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://sportsperspectives.com/2017/09/10/pra-health-sciences-inc-prah-shares-sold-by-century-capital-management-llc.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply